Gelder Mark S. MD 4
4 · Onconova Therapeutics, Inc. · Filed Feb 8, 2023
Insider Transaction Report
Form 4
Gelder Mark S. MD
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2023-02-07+5,833→ 11,729 total - Tax Payment
Common Stock
2023-02-07$1.36/sh−1,242$1,689→ 10,487 total - Exercise/Conversion
Restricted Stock Units
2023-02-07−5,833→ 11,667 total→ Common Stock (5,833 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On February 7, 2022 the reporting person was granted 17,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.